Catalyst Wire Dossier Catalyst Wire Dossier

Investigational vaccine with recombinant human albumin (rHA)

recombinant human albumin-based vaccine · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Investigational vaccine with recombinant human albumin (rHA), covering 2017-03-15 to 2017-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) [Phase 2]

See pricing